Sanofi (SNYNF) Liabilities from Discontinued Operations (2009 - 2025)
Sanofi (SNYNF) posted Liabilities from Discontinued Operations of 2263919.38 for Q2 2025, down 99.9% sequentially from 2277176797.75 in Q4 2024.
Sanofi (SNYNF) Liabilities from Discontinued Operations (2009 - 2025) Analysis & Trends
Sanofi (SNYNF) has 17 years of Liabilities from Discontinued Operations data on file, last reported at 2263919.38 in Q2 2025.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 2263919.38 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 2263919.38 (changed N/A YoY) and the FY2024 annual result came in at 2277176797.75, up 16093.45% from the prior year.
- Liabilities from Discontinued Operations slipped to 2263919.38 in Q2 2025 per SNYNF's latest filing, from 2277176797.75 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 2277176797.75 in Q4 2024, with the low at 2263919.38 in Q2 2025.
- Average Liabilities from Discontinued Operations over 5 years is 340533923.09, with a median of 18139963.7 recorded in 2022.
- Year-over-year, Liabilities from Discontinued Operations dropped 16.32% in 2022 and jumped 16180.41% in 2024.
- Sanofi's Liabilities from Discontinued Operations stood at 21676885.87 in 2021, then plunged by 52.93% to 10202473.65 in 2022, then jumped by 37.1% to 13987218.82 in 2023, then jumped by 16180.41% to 2277176797.75 in 2024, then plunged by 99.9% to 2263919.38 in 2025.
- Business Quant data shows SNYNF's Liabilities from Discontinued Operations at 2263919.38 in Q2 2025, 2277176797.75 in Q4 2024, and 13987218.82 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Dec 31, 2024 | 2.28 Bn |
| Dec 31, 2024 | 2.28 Bn |
| Dec 31, 2023 | 13.99 Mn |
| Dec 31, 2023 | 13.99 Mn |
| Jun 30, 2023 | 40.29 Mn |
| Jun 30, 2023 | 40.29 Mn |
| Dec 31, 2022 | 10.20 Mn |
| Dec 31, 2022 | 10.20 Mn |
| Jun 30, 2022 | 18.14 Mn |
| Jun 30, 2022 | 18.14 Mn |
| Jun 30, 2021 | 21.68 Mn |
| Jun 30, 2021 | 21.68 Mn |
| Dec 31, 2020 | 38.15 Mn |
| Dec 31, 2020 | 38.15 Mn |
| Jun 30, 2020 | 7.71 Mn |
| Jun 30, 2020 | 7.71 Mn |
| Dec 31, 2019 | 6.64 Mn |
| Dec 31, 2019 | 6.64 Mn |